269 related articles for article (PubMed ID: 16499654)
1. Detection of bacterial strains producing sulbactam- or tazobactam-sensitive beta-lactamases by the use of disks containing the inhibitors alone instead of combining them with antibiotics.
Banic S
APMIS; 2006 Jan; 114(1):3-9. PubMed ID: 16499654
[TBL] [Abstract][Full Text] [Related]
2. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
Sader HS; Tosin I; Sejas L; Miranda E
Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
[TBL] [Abstract][Full Text] [Related]
3. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanic acid and sulbactam combined with ampicillin and piperacillin against beta-lactamase producing anaerobic bacteria.
Nord CE
J Chemother; 1989 Jul; 1(4 Suppl):273-5. PubMed ID: 16312398
[No Abstract] [Full Text] [Related]
4. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Thomson KS; Moland ES
Antimicrob Agents Chemother; 2001 Dec; 45(12):3548-54. PubMed ID: 11709338
[TBL] [Abstract][Full Text] [Related]
5. In vitro activities of piperacillin or cefoperazone alone and in combination with beta-lactamase inhibitors against gram-negative bacilli.
Kuo HY; Wang FD; Yen YF; Lin ML; Liu CY
New Microbiol; 2009 Jan; 32(1):49-55. PubMed ID: 19382669
[TBL] [Abstract][Full Text] [Related]
6. Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care hospital.
Petrikkos G; Markogiannakis A; Papaparaskevas J; Daikos GL; Stefanakos G; Zissis NP; Avlamis A
Int J Antimicrob Agents; 2007 Jan; 29(1):34-8. PubMed ID: 17189092
[TBL] [Abstract][Full Text] [Related]
7. In vitro efficacy of ceftriaxone/sulbactam against Escherichia coli isolates producing CTX-M-15 extended-spectrum beta-lactamase.
Shahid M; Singhai M; Malik A; Shukla I; Khan HM; Shujatullah F; Tahira F
J Antimicrob Chemother; 2007 Jul; 60(1):187-8. PubMed ID: 17491002
[No Abstract] [Full Text] [Related]
8. Piperacillin tazobactam compared with co-amoxiclav, ampicillin plus sulbactam and timentin against beta-lactamase-producing clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca.
Traub WH; Leonhard B
Chemotherapy; 1995; 41(5):345-52. PubMed ID: 8521736
[TBL] [Abstract][Full Text] [Related]
9. Double-disk synergy test positivity in Stenotrophomonas maltophilia clinical strains.
Hejnar P; Kolár M; Chmela Z
Folia Microbiol (Praha); 2004; 49(1):71-4. PubMed ID: 15114869
[TBL] [Abstract][Full Text] [Related]
10. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
Gatermann S; Marre R
Infection; 1991; 19(2):106-9. PubMed ID: 1646771
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility survey of piperacillin/tazobactam and some beta-lactam comparators in Italy.
Stefani S; Bonfiglio G; Bianchi C; Zollo A; Nicoletti G
Drugs Exp Clin Res; 1998; 24(2):105-13. PubMed ID: 9675551
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of ceftriaxone plus tazobactam against members of Enterobacteriaceae.
Prakash SK; Arora V; Prashad R; Sharma VK
J Assoc Physicians India; 2005 Jul; 53():595-8. PubMed ID: 16190126
[TBL] [Abstract][Full Text] [Related]
13. Correlation of in vitro susceptibility testing results for amoxicillin-clavulanate and ampicillin-sulbactam using a panel of beta-lactamase-producing Enterobacteriaceae.
Siu LK; Cheng WL; Ho PL; Ng WS; Chau PY; Lo JY
APMIS; 1998 Sep; 106(9):917-20. PubMed ID: 9808419
[TBL] [Abstract][Full Text] [Related]
14. Post-antibiotic and post-beta-lactamase inhibitor effects of ceftazidime plus sulbactam on extended-spectrum beta-lactamase-producing Gram-negative bacteria.
Lavigne JP; Bonnet R; Michaux-Charachon S; Jourdan J; Caillon J; Sotto A
J Antimicrob Chemother; 2004 Apr; 53(4):616-9. PubMed ID: 14985275
[TBL] [Abstract][Full Text] [Related]
15. Why clinically used tazobactam and sulbactam are poor inhibitors of OXA-10 beta-lactamase: Raman crystallographic evidence.
Totir MA; Cha J; Ishiwata A; Wang B; Sheri A; Anderson VE; Buynak J; Mobashery S; Carey PR
Biochemistry; 2008 Apr; 47(13):4094-101. PubMed ID: 18324783
[TBL] [Abstract][Full Text] [Related]
16. In vivo efficacies of beta-lactam-beta-lactamase inhibitor combinations against a TEM-26-producing strain of Klebsiella pneumoniae.
Rice LB; Carias LL; Shlaes DM
Antimicrob Agents Chemother; 1994 Nov; 38(11):2663-4. PubMed ID: 7872765
[TBL] [Abstract][Full Text] [Related]
17. A kinetic study on the interaction between tazobactam (a penicillanic acid sulphone derivative) and active-site serine beta-lactamases.
Perilli M; Franceschini N; Bonfiglio G; Segatore B; Stefani S; Nicoletti G; Perez MM; Bianchi C; Zollo A; Amicosante G
J Enzyme Inhib; 2000; 15(1):1-10. PubMed ID: 10850951
[TBL] [Abstract][Full Text] [Related]
18. The activity of a sulphone beta-lactamase inhibitor, YTR 830.
Moosdeen F; Williams J; Yamabe S
Chemioterapia; 1987 Jun; 6(2 Suppl):206-7. PubMed ID: 2855613
[No Abstract] [Full Text] [Related]
19. Activity of beta-lactam beta-lactamase inhibitor combinations against extended spectrum Beta-lactamase producing Enterobacteriaceae in urinary isolates.
Afridi FI; Farooqi BJ
J Coll Physicians Surg Pak; 2012 Jun; 22(6):358-62. PubMed ID: 22630093
[TBL] [Abstract][Full Text] [Related]
20. Effect of pO2 and pH on synergy of tazobactam and beta-lactam antibiotics against beta-lactamase producing Enterobacteriaceae.
König C; Blaser J
J Antimicrob Chemother; 1995 Sep; 36(3):513-9. PubMed ID: 8830015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
